Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970083 | 0.88 | ACKR3 (0.45) | ACKR3TLR8DYRK2LMNATP53 | |
| SCHEMBL3963837 | 0.85 | FGFR1 (0.44) | FGFR1 | |
| SCHEMBL3965330 | 0.84 | SLC2A1 (0.43) | FGFR1DRD2DRD3DRD4 | |
| SCHEMBL3971053 | 0.84 | SLC2A1 (0.43) | FGFR1DRD2DRD3DRD4 | |
| SCHEMBL3971739 | 0.81 | VCP (0.46) | DYRK2FGFR1DRD2DRD3DRD4 | |
| SCHEMBL3969374 | 0.81 | LCK (0.41) | DYRK2FGFR1DRD2DRD3DRD4 | |
| SCHEMBL3962145 | 0.81 | ACKR3 (0.51) | ACKR3TLR8DYRK2DRD2DRD3 | |
| SCHEMBL3969289 | 0.79 | FGFR1 (0.44) | ACKR3TLR8FGFR1 | |
| SCHEMBL4085203 | 0.77 | ACKR3 (0.42) | ACKR3DYRK2LMNATP53 | |
| SCHEMBL3964488 | 0.76 | LCK (0.43) | TP53FGFR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989200-B1 | [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7547691-B2 | [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases | ELI LILLY AND COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | ELI LILLY AND COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | NFKBIA, IKBKB, IKBKG | ACKR3 2346/4885TLR8 932/4885DYRK2 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.